药明康德(02359.HK)股东因违反承诺减持致歉
药明康德(02359.HK)(603259.SH)公布,於上周五(11日)收到公司股东上海瀛翊投资中心通知及致歉,指上海瀛翊於5月14日至6月8日期间,通过上海证券交易所集中竞价交易系统减持公司合共近1,724.97万股A股股份,占公司总股本约0.6962%,减持价格区间为每股143.49至176.88元人民币(下同),总金额为28.94亿元。
由於上海瀛翊在实施本次减持之前未能遵守其作为委托投票方作出的有关减持公司股份的相关承诺,未提前通知公司,也没有提前15个交易日通过公司披露减持计划履行公告等相关程序,违反减持承诺。
公司表示,上海瀛翊自查确认上述违反承诺的减持行为後,已立即停止减持行为,并已责令相关人员学习相关法律、法规,以杜绝此类事件再次发生。截至目前,上海瀛翊持有药明康德417.46万股A股股份,占公司总股本约0.1419%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.